Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences: Neurology

Cholinergic and dopaminergic PET imaging of gait in Parkinson disease

Martijn Muller, Roger Albin, Robert Koeppe, Michael Kilbourn, Kirk Frey and Nicolaas Bohnen
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 609;
Martijn Muller
1University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Albin
2University of Michigan/VA, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Koeppe
1University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kilbourn
1University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirk Frey
1University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolaas Bohnen
2University of Michigan/VA, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

609

Objectives To investigate the relationship between gait, striatal binding of [11C]-dihydrotetrabenazine (DTBZ), and thalamic and cerebellar [11C]-methyl-4-piperidinyl propionate (PMP) activity in Parkinson disease (PD) patients.

Methods Mild to moderate PD patients (N =28; 0 F; 69.1 ± 7.6 yrs; H & Y 1-3) underwent [11C]DTBZ and [11C]PMP PET brain imaging and gait assessment. Temporal gait parameters (Gait Speed, Cadence, Step Time, Stance Time, and Swing Time) were acquired with a pressure-sensitive foot sensor system (Biopac). DTBZ PET data were analyzed using bolus-infusion equilibrium kinetic modeling with the global neocortex as reference region. PMP uptake ratio was calculated as late versus early radiotracer retention. Temporal gait parameters, striatal DTBZ distribution volume (DV), and cerebellar and thalamic PMP uptake ratio were statistically correlated (Spearman).

Results Decreased cerebellar PMP uptake ratio was associated with decreased cadence (ρ=0.440, p=0.022) and increased step time (ρ=-0.501, p=0.008) and swing time (ρ=-0.525, p=0.005). Decreased thalamic PMP uptake ratio was associated with increased step time (ρ=-0.402, p=0.038) and borderline significant with decreased cadence (ρ=0.362, p=0.097). There were no significant correlations between any of the temporal gait parameters and DTBZ-DV.

Conclusions Unlike dopaminergic denervation of the striatum, cholinergic denervation of the cerebellum and the thalamus correlates with temporal aspects of gait in PD patients. PD patients take fewer steps per minute and step time and leg swing time increases. These temporal effects are especially correlated with cerebellar cholinergic denervation. The cerebellum is an important center for timing and mobility control. The thalamus receives cholinergic projections from the pedunculopontine nucleus, an important locomotor center in the brain stem. Cholinergic denervation of the cerebellum and thalamus, rather than striatal dopaminergic denervation, appears to affect these aspects of gait in PD.

Research Support Department of Veterans Affair

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cholinergic and dopaminergic PET imaging of gait in Parkinson disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Cholinergic and dopaminergic PET imaging of gait in Parkinson disease
Martijn Muller, Roger Albin, Robert Koeppe, Michael Kilbourn, Kirk Frey, Nicolaas Bohnen
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 609;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cholinergic and dopaminergic PET imaging of gait in Parkinson disease
Martijn Muller, Roger Albin, Robert Koeppe, Michael Kilbourn, Kirk Frey, Nicolaas Bohnen
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 609;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences: Neurology

  • Unexpected activation of Wernicke’s area in tinnitus patients
  • Comparison of cerebral grey matter atrophy and hypometabolism in posterior cortical atrophy using voxel-based morphometry in MRI and FDG-PET
  • Precuneus amyloid burden is associated with decreased bilateral frontal activation and default network suppression in healthy adults
Show more Neurosciences: Neurology

Neurology: Movement Disorders

  • Mapping the relationship between β-amyloid load and cognition-related metabolic activity in Parkinson’s disease: [11C]-PIB and [18F]-FDG PET studies
  • Association between lower α4β2* nicotinic acetylcholine receptor binding and nonmotor symptoms in early drug naive Parkinson disease: A 2-[18F]F-A-85380 (2FA) PET study
Show more Neurology: Movement Disorders

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire